Prescription trends for obesity medications surge, tied to growing interest in GLP-1 drugs

This post was originally published on News-medical.net

You will shortly be re-directed to the publisher's website

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest influences prescription trends.